Skip to main content
Skip table of contents

Respiratory Infection Practice Standard Summary

The Respiratory Infection (RI) Practice Standard supports the diagnosis and treatment of respiratory infection conditions. These include COVID-19, upper respiratory infection, bronchitis, sinusitis, pharyngitis, pertussis, influenza, pneumonia, subacute cough due to post nasal drip, bronchospasm, or GERD, and chronic cough. 

Background 

The RI Practice Standard will launch if all of the following criteria are met:

  • Patient is between the ages of 18 and 64

  • Based on the patient’s Chief Complaint, the diagnoses presented for the provider’s consideration by machine learning relate to COVID-19, upper respiratory infection, bronchitis, sinusitis, pharyngitis, influenza, pneumonia, or pharyngitis

Clinical Content

Medical Interview Summary

The RI Practice Standard starts by asking every patient about COVID-19: vaccinations, past infection history, recent exposure and recent test results. It then asks about annual flu vaccination history and the interview splits based on whether they are symptomatic or asymptomatic. Symptomatic patients will receive questions about respiratory symptoms, while asymptomatic patients will receive questions about COVID-19 or influenza exposure, depending on the circumstance.

A standard set of questions is asked of all symptomatic patients, in order to obtain a basic review of the fundamental respiratory systems (duration since onset of symptoms, constitutional, sinuses, throat, chest). Conditional follow up questions may be asked (e.g. if a patient reports a cough, it will ask about duration and sputum production). 

If the patient reports shortness of breath, the RI Practice Standard asks about red flags, such as dyspnea with daily activity, dyspnea with light activity, and difficulty speaking full sentences. Some symptom clusters warrant a referral to urgent care or the emergency department, such as shortness of breath, fever, sweats, chills, productive cough, and chest pain which are concerning for pneumonia. Some symptom clusters warrant a referral to in person primary care or urgent care for testing instead of empiric treatment, such as intermediate probability Centor scores and intermediate likelihood of influenza when treatment may be recommended with a positive rapid influenza test.

At the end of the automated interview, a diagnosis will be presented for the provider’s consideration, along with relevant prescription medication(s), and documentation to support the provider’s medical decision making. In addition, referrals and lab suggestions will be displayed. Some symptom combinations will recommend in person exam or testing. Based on the diagnosis selected by the provider, some care plans will be entered in for the patient’s education. In cases like sinusitis where there is the possibility of having a bacterial or viral cause, the care plan will be imported by the provider in the form of a text expander. A reminder in the console will tell the provider whether they have to import their own care plan. The provider can choose to use the suggestions provided, or change them based on their clinical decision making. 

Virtual Care Management Pearls

  • Acute sinusitis, bacterial

    • Bacterial sinusitis symptoms include the following

      • Sinus pressure and nasal congestion lasting ≥10 days

      • Sinus pressure and nasal congestion lasting 8-10 days with double-sickening and either increased nasal secretions, fever, or sinus headache worsening with bending forward

      • Nasal discharge amount or color should not influence diagnosis

  • Acute sinusitis, viral

    • Viral sinusitis symptoms include the following

      • Sinus pressure and nasal congestion without sore throat, cough, shortness of breath, chest pain and:

        • Symptom onset <10 days

      • Most sinusitis infections are viral

      • Nasal discharge amount or color should not influence diagnosis

      • Note that most other acute combined symptoms (sinus pressure and congestion with other symptoms such as sore throat or cough) are often diagnosed as URI

  • Acute Upper Respiratory Infection (URI) 

    • Suspect in patients in which a mix of sinus, pharyngeal, or lower airway symptoms are present

    • Nasal discharge amount or color should not influence diagnosis

    • Most symptomatic respiratory infections that do not satisfy the specific diagnostic criteria for the other diagnoses in the RI Practice Standard are diagnosed as acute URI

  • Acute Bronchitis

    • Suspect in patients with cough for 2-3 weeks, with mild lower respiratory symptoms not concerning for pneumonia

    • Sputum production, amount, or color should not influence diagnosis

  • COVID-19 positive, symptomatic

    • COVID-19 positive by at-home or NAAT testing history:

      • The RI Practice Standard assesses if the patient may be a candidate for oral antiviral medication using age, race/ethnicity, vaccination history, duration of symptoms and questions about medical conditions that put them at high risk for complications from COVID-19 infection, following CDC guidance

      • If oral antiviral treatment criteria are satisfied, the RI Practice Standard will present for consideration treatment with paxlovid or molnupiravir, and provide chat suggestions for the clinician to confirm current medications during the visit, for safe prescribing of the oral antiviral options

  • COVID-19 positive, asymptomatic

    • COVID-19 positive by at-home or NAAT testing history, asymptomatic

      • Antiviral treatment not recommended

  • COVID-19 exposed, asymptomatic

    • Asymptomatic, exposed by CDC criteria, COVID-19 negative by at-home or NAAT testing history, or untested

  • COVID-19 concerns, symptomatic, not positive

    • Symptomatic, COVID-19 negative by at-home or NAAT testing history, or untested:

      • Suspect possible COVID-19 in most symptomatic respiratory infection patients

      • Common symptoms include fever, chills, cough, shortness of breath, fatigue, sore throat, runny nose, congestion, body aches, headache, vomiting, diarrhea, loss of smell and taste, COVID-19 exposure, and slower development of symptoms

  • Influenza

    • Asymptomatic influenza exposure

      • Antiviral post-exposure prophylaxis treatment is recommended when all of these are true:

        • Asymptomatic

        • First influenza exposure ≤48 hours ago

        • High medical risk for severe complications from influenza

        • No flu shot, or flu shot received <2 weeks prior

    • Symptomatic possible influenza

      • The RI Practice Standard uses all combinations of the following criteria to categorize into evaluation and treatment categories

      • Influenza “seasons” of the year

        • Peak-season: December, January, February

        • Shoulder-season: October, November, March, April, May

        • Off-season: June, July, August, September

      • Exposure to influenza

      • Duration since onset of symptoms

      • Clinical likelihood that symptoms are consistent with influenza infection

        • A clinical decision rule identifies symptoms to determine influenza likelihood

          • 2 points for fever + cough (no partial credit)

          • 2 points for myalgias

          • 1 point for duration <48h

          • 1 point for chills/sweats

        • Scoring system:

          • 0-2 points LOW (8%) flu likelihood

          • 3 points MODERATE (30%) flu likelihood

          • 4-6 points HIGH (59%) flu likelihood

      • Medical risk for severe complications from influenza infection

        • Assessment of age, race/ethnicity, and questions about medical conditions that put them at high risk for complications from Influenza infection.  

    • The RI Practice Standard sorts all combinations of the criteria above into one of these categories: 

      • Empiric treatment: 

        • The highest likelihood and/or highest risk of influenza; empiric antiviral treatment is recommended

        • When empiric treatment is recommended, the patient is advised to start the medication as soon as possible, and is also advised to seek in person care for confirmatory influenza testing

      • Refer for testing: 

        • Possible influenza, the patient may qualify for antiviral treatment, but an influenza test is needed to make that determination

        • These patients are referred to in person care for testing

      • No treatment and no referral: 

        • These categories do not support antiviral treatment or testing 

        • The RI Practice Standard will result in a different respiratory diagnosis, without any specific callout of influenza concerns

  • Pertussis

    • Overall symptom onset >10 days, cough duration 2-8 weeks, barking cough, coughing spasms / paroxysms

    • In suspected cases the patient is asked about exposure to pertussis

  • Pharyngitis

    • If a patient reports a sore throat, the RI Practice Standard may ask questions and calculate the Centor score, depending on the presence of other symptoms 

    • For cases of possible strep throat, the RI Practice Standard will provide a chat suggestion for the clinician to ask for a photo of the throat during the clinician visit

      • Centor score 4: Possible strep throat, recommend empiric antibiotic treatment

      • Centor score 3: Refer for in-person care for strep testing

      • Centor score 2 and no sinus congestion, pressure, nasal discharge, conjunctivitis, new rash: Refer for in-person care for strep testing

      • Centor score 2 and any viral symptoms above: Non-pharyngitis diagnosis 

      • Centor score 0-1 and no sinus congestion, pressure, nasal discharge, conjunctivitis, new rash: Viral pharyngitis

      • Centor score 1 and any viral symptoms above: Non-pharyngitis diagnosis

  • Pneumonia

    • Fever, productive cough, sweats/chills, and lower respiratory symptoms such as shortness of breath, tachypnea, chest pain 

    • Concern for possible pneumonia needs an in person evaluation and / or chest imaging, and patients are not candidates for empiric treatment

    • The console suggests cough and refer to in person care given a diagnosis of pneumonia via telemedicine is difficult

  • Subacute cough

    • Cough duration 3-8 weeks

    • The RI Practice Standard asks about post-nasal drainage, wheezing, and acid reflux

  • Chronic Cough

    • Cough duration ≥8 weeks

Medication Guidelines

  • Acute sinusitis, bacterial

    • OTC recommendations noted in chat suggestions

    • Rx antibiotics:

      • Amoxicillin/clavulanate 875mg/125mg BID x 7 days (first line)

      • Doxycycline 100mg BID x 7 days (if pcn allergy)

      • Macrolides and trimethoprim-sulfamethoxazole are not recommended due to antibiotic resistance

    • Not recommended: Oral corticosteroids

  • Acute sinusitis, viral

    • OTC recommendations noted in chat suggestions

    • Rx: Optional benzonatate 100mg TID PRN #21 with guaifenesin

    • Not recommended: Antibiotics, oral corticosteroids

  • Acute Upper Respiratory Infection (URI)

    • OTC recommendations noted in chat suggestions

    • Rx: Optional benzonatate 100mg TID PRN #21 with guaifenesin

    • Not recommended: Antibiotics, oral corticosteroids

  • Acute Bronchitis 

    • OTC recommendations noted in chat suggestions

    • Rx: Optional benzonatate 100mg TID PRN #21 with guaifenesin

    • Not recommended: Antibiotics

    • Not recommended: Oral or inhaled corticosteroids or albuterol inhaler (unless indicated for asthma or related pulmonary disease)

  • COVID-19 positive, symptomatic

    • OTC recommendations noted in chat suggestions

    • Rx: Optional benzonatate 100mg TID PRN #21 with guaifenesin

    • Rx with antiviral: 

      • Paxlovid (EUA) 300 mg (150 mg x 2)-100 mg tablet, Take two 150 mg tablets of nirmatrelvir with one 100 mg tablet of ritonavir twice daily for 5 days (first line)

      • Molnupiravir 200 mg capsule (EUA), 4 caps by mouth every 12 hours for 5 days (second line if paxlovid is contraindicated)

    • Not recommended: Oral or inhaled corticosteroids (unless indicated for asthma or related pulmonary disease), non-proven treatments including antibacterials, hydroxychloroquine, ivermectin

  • COVID-19 positive, asymptomatic

    • Not recommended: Antiviral treatment, corticosteroids, non-proven treatments

  • COVID-19 exposed, asymptomatic

    • Not recommended: Prophylaxis, antiviral treatment, corticosteroids, non-proven treatments

  • COVID-19 concerns, symptomatic, not positive

    • Not recommended: Antiviral treatment, corticosteroids, non-proven treatments

  • Influenza asymptomatic post-exposure prophylaxis

    • Rx: Oseltamivir 75mg daily x 7 days

  • Influenza symptomatic

    • OTC recommendations noted in chat suggestions

    • Rx: Optional benzonatate 100mg TID PRN #21 with guaifenesin

    • Rx for “empiric treatment” recommendation: 

      • Oseltamivir 75mg BID x 5 days (preferred)

      • Baloxavir 40mg (40-80kg) or 80mg (>80kg) single dose (alternate)

  • Pertussis symptomatic

    • Antibiotic treatment is not recommended without evaluation and testing

  • Pharyngitis

    • Empiric strep throat treatment:

      • OTC recommendations noted in chat suggestions

      • Rx:

        • Penicillin V 500mg BID x10 days (first line)

        • Amoxicillin 500mg BID x 10 days (second line)

        • If allergic to penicillins: 

          • Cephalexin 500mg BID x 10 days

          • Azithromycin 500mg daily x 5 days

      • Not recommended: Oral corticosteroids

    • Viral pharyngitis:

      • OTC recommendations noted in chat suggestions

      • Not recommended: Antibiotics, oral corticosteroids

  • Subacute cough

    • Post nasal drainage

      • OTC recommendations noted in chat suggestions

      • OTC: Optional oxymetazoline maximum 3 days

    • Airway inflammation

      • Rx: Albuterol sulfate HFA 90 mcg/actuation aerosol inhaler, Inhale 2 puffs every 4 - 6 hours as needed for cough, wheezing, or shortness of breath

    • Acute or chronic GERD symptoms

      • OTC: Omeprazole 20mg daily for 2-4 weeks

    • Not recommended: Antibiotics, oral corticosteroids

Follow-up Recommendations to be Discussed with the Patient

  • Acute sinusitis, bacterial

    • Urgent care or emergency department:

      • Fever >102 for >5 days, vision changes, facial swelling or redness, worsening severe headache, confusion, disorientation, unusual sleepiness, stiff painful neck 

    • Counsel on current CDC recommendations for isolation and COVID-19 testing

  • Acute sinusitis, viral

    • Follow up with our clinic

      • High persistent fevers, increasing sinus pain, overall worsening instead of improvement

    • Urgent care or emergency department:

      • Fever >102 for >5 days, vision changes, facial swelling or  redness, worsening severe headache, confusion, disorientation, unusual sleepiness, stiff painful neck 

    • Counsel on current CDC recommendations for isolation and COVID-19 testing

  • Acute Upper Respiratory Infection (URI)

    • Counsel on current CDC recommendations for isolation and COVID-19 testing

  • Acute Bronchitis

    • Follow up with our clinic or in person

      • Cough >3 weeks

    • Urgent care or emergency department

      • Fever >100.4 for >5 days, worsening shortness of breath

    • Counsel on current CDC recommendations for isolation and COVID-19 testing

  • Chronic cough

    • In person PCP

      • Referral for in person exam and possible chest X-ray

  • COVID-19 positive, symptomatic

    • Urgent care or emergency department 

      • Pulse oximetry <94%

      • Positive answers to pulmonary red flag questions

      • Severe weakness or shortness of breath develops after visit

    • If paxlovid is recommended, chat suggestions are provided to clinicians describing paxlovid rebound and recommending re-isolation

    • Counsel on current CDC recommendations for isolation

    • Follow up if symptoms not resolving at end of recommended isolation

  • COVID-19 positive, asymptomatic

    • Counsel on current CDC recommendations for isolation

    • Re-isolate or continue isolation if symptoms develop

  • COVID-19 exposed, asymptomatic

    • Counsel on CDC recommendations for quarantine and testing

    • Isolate if symptoms develop

  • COVID-19 concerns, symptomatic, not positive

    • Counsel on current CDC recommendations for isolation and COVID-19 testing

  • Influenza exposure, asymptomatic:

    • Follow up with our clinic

      • If symptoms develop after visit, whether or not post-exposure prophylaxis is prescribed: fevers, chills, sweats, body aches, cough or other respiratory symptoms

  • Influenza symptomatic

    • Urgent care or emergency department 

      • Pulse oximetry <94%

      • Positive answers to pulmonary red flag questions

    • In person PCP or urgent care

      • When treated with empiric antiviral, start antiviral right away and also refer for in-person testing for influenza and COVID-19 for confirmation

      • When not treated empirically with antiviral, but may qualify if influenza test is positive, refer for in-person testing for influenza and COVID-19

    • Counsel on current CDC recommendations for isolation and COVID-19 testing

  • Pertussis symptomatic

    • In person PCP

      • Referral for in person exam and testing

      • Suspected cases should be reported to the local Health Department prior to laboratory confirmation via in person provider

  • Pharyngitis

    • Urgent care or emergency department

      • If worsening sore throat, fever, difficulty breathing or swallowing saliva after visit

    • PCP or urgent care

      • If sore throat is not improving or is worse after 72 hours of empiric antibiotics for strep throat

      • If indeterminate strep throat, refer for strep testing

    • Follow up with us or PCP

      • If viral pharyngitis and sore throat persists >7 days

    • Counsel on current CDC recommendations for isolation and COVID-19 testing

  • Pneumonia

    • Urgent care

      • Referral for in person exam and possible chest X-ray

ICD-10 Codes Provided

Associated Available TextExpanders (if needed)

Please see your institution's Text Snippet document on available options.

Chat and Documentation Suggestions

In addition to presenting diagnostic and treatment suggestions for consideration by the provider, the RI Practice Standard presents chat and documentation suggestions to the provider for consideration based on previous machine learning.. The suggestions are tied to the selection of a diagnosis suggested for consideration by the provider. For example, if the RI Practice Standard suggests Acute Upper Respiratory Infection as the ICD-10 diagnosis AND the provider selects Acute Upper Respiratory Infection as their diagnosis, the chat and documentation suggestions for consideration will relate primarily to Acute Upper Respiratory diagnosis and treatment.

Citations

  1. Centers for Disease Control and Prevention (2022, September 28). COVID-19 Testing: What You Need to Know. Centers for Disease Control and Prevention. Retrieved October 5, 2022, from https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html  

  2. Centers for Disease Control and Prevention (2021, Dec. 27). Healthcare Workers: Information on COVID-19. Retrieved October 5, 2022, from https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html

  3. Centers for Disease Control and Prevention (2022, June 27). Strep Throat: All You Need to Know. Retrieved October 5, 2022, from https://www.cdc.gov/groupastrep/diseases-public/strep-throat.html#:~:text=Close%20contact%20with%20another%20person,other%20people%20in%20their%20household  

  4. Centers for Disease Control and Prevention (2022, September 30). Weekly US Map: Influenza Summary Update. Retrieved October 5, 2022, from https://www.cdc.gov/flu/weekly/usmap.htm  

  5. del Rio, C., MD, & Malani, P. N., MD (2020). COVID-19—New Insights on a Rapidly Changing Epidemic. JAMA. https://doi.org/10.1001/jama.2020.3072  

  6. Ebell, M. H., Afonso, A. M., Gonzales, R., Stein, J., Genton, B., & Senn, N. (2012). Development and validation of a clinical decision rule for the diagnosis of influenza. Journal of the American Board of Family Medicine : JABFM, 25(1), 55–62. https://doi.org/10.3122/jabfm.2012.01.110161  

  7.  Fashner, J., Ericson, K., & Werner, S. (2012). Treatment of the common cold in children and adults. American family physician, 86(2), 153–159. 

  8. Meneghetti, A., MD, & Mosenifar, Z., MD, FACP, FCCP (2020, September 11). Upper Respiratory Tract Infection Treatment & Management. Medscape. Retrieved October 5, 2022, from https://emedicine.medscape.com/article/302460-treatment#d15  

  9. Puhakka, T., Mäkelä, M. J., Alanen, A., Kallio, T., Korsoff, L., Arstila, P., Leinonen, M., Pulkkinen, M., Suonpää, J., Mertsola, J., & Ruuskanen, O. (1998). Sinusitis in the common cold. The Journal of allergy and clinical immunology, 102(3), 403–408. https://doi.org/10.1016/s0091-6749(98)70127-7 

  10. Rettner, R. (2020). How does the new coronavirus compare with the flu? Live Science. Retrieved October 5, 2022, from https://www.livescience.com/new-coronavirus-compare-with-flu.html

  11. Sheikh, K., Watkins, D., Wu, J., & Gröndahl, M. (2020, February 28). How Bad Will the Coronavirus Outbreak Get? Here Are 6 Key Factors. The New York Times. Retrieved October 5, 2022, from https://www.nytimes.com/interactive/2020/world/asia/china-coronavirus-contain.html  

  12. Smith, S. M., Schroeder, K., & Fahey, T. (2014). Over-the-counter (OTC) medications for acute cough in children and adults in community settings. The Cochrane database of systematic reviews, 2014(11), CD001831. https://doi.org/10.1002/14651858.CD001831.pub5

JavaScript errors detected

Please note, these errors can depend on your browser setup.

If this problem persists, please contact our support.